Whole-Genome Sequencing Identifies PPARGC1A as a Putative Modifier of Cancer Risk in BRCA1/2 Mutation Carriers

Simple Summary In search of genetic factors that affect cancer risks in BRCA carriers, we carried out the first whole-genome sequencing study in a unique registry of familial ovarian cancer, selected to enrich with BRCA1/2 carriers. We are the first to survey rare variants, particularly the non-coding variants for BRCA modifier genes and identified PPARGC1A, a master regulator of mitochondrial biogenesis, as a novel putative BRCA modifier. This finding can help improve cancer risk prediction and provide personalized preventive care for BRCA carriers. Abstract While BRCA1 and BRCA2 mutations are known to confer the largest risk of breast cancer and ovarian cancer, the incomplete penetrance of the mutations and the substantial variability in age at cancer onset among carriers suggest additional factors modifying the risk of cancer in BRCA1/2 mutation carriers. To identify genetic modifiers of BRCA1/2, we carried out a whole-genome sequencing study of 66 ovarian cancer patients that were enriched with BRCA carriers, followed by validation using data from the Pan-Cancer Analysis of Whole Genomes Consortium. We found PPARGC1A, a master regulator of mitochondrial biogenesis and function, to be highly mutated in BRCA carriers, and patients with both PPARGC1A and BRCA1/2 mutations were diagnosed with breast or ovarian cancer at significantly younger ages, while the mutation status of each gene alone did not significantly associate with age of onset. Our study suggests PPARGC1A as a possible BRCA modifier gene. Upon further validation, this finding can help improve cancer risk prediction and provide personalized preventive care for BRCA carriers.